bpc-157 ind status fda panel votes to ease restrictions on peptide This Week at FDA: HHS

Sequence (Selank): Thr-Lys-Pro-Arg-Pro-Gly-Pro

For chronic conditions, full assessment should occur after a complete 812 week cycle

The committee members who voted yes generally believed the risks to be minimal, while those who voted no tended to worry about safety risks and effectiveness, and expressed concern that adding the peptide to the compounding list would create a false impression that it has been evaluated with the same rigorous standards as an FDA-approved drug

pain reduction radical scavenger and antioxidant actions gastric mucosa healing stomach cell protection against noxious agents improving the healing of intestinal tissues increased vessel recruitment following injury induction improving short-bowel syndrome Unofficially, the peptide has also been claimed to help burn fat, increase muscle, heal the heart, lower blood pressure, help with erectile dysfunction, and increase HGH levels, but there is no data to suggest that, even from lab studies